Microenvironmental Regulation of Proliferation in Multicellular Spheroids Is Mediated through Differential Expression of Cyclin-Dependent Kinase Inhibitors

Cancer Research

Volumn 64, Issue 5, 2004, Pages 1621-1631

  LaRue, Karen E A ^a   Khalil, Mona ^a   Freyer, James P ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P18; PROTEIN P21; PROTEIN P27; DNA;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL FRACTIONATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; MULTICELLULAR SPHEROID; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPHEROID CELL; STRESS; TUMOR GROWTH; ANIMAL; CELL DIVISION; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; MELANOMA; PATHOLOGY; SERODIAGNOSIS; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; DNA, NEOPLASM; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA; MICE; PRECIPITIN TESTS; SPHEROIDS, CELLULAR;

EID: 1642359043     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-2902-2     Document Type: Article

References (95)

1. Sutherland, R. M. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science (Wash. DC), 240: 177-184. 1988.
2. Freyer, J. P. Spheroids in radiobiology research. In: R. Bjerkvig (ed.), Spheroid Culture in Cancer Research, pp. 217-275. Boca Raton: CRC Press, 1992.
3. Mueller-Klieser, W. 3-dimensional cell cultures: from molecular mechanisms to clinical applications. Am. J. Physiol. Cell. Physiol., 42: C1109-C1123, 1997.
4. Brown, J. M., and Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res., 58: 1408-1416, 1998.
5. Vaupel, P. W. The influence of tumor blood flow and microenvironmental factors on the efficacy of radiation, drugs and localized hyperthermia. Klin. Padiatr., 209: 243-249, 1997.
6. Freyer, J. P. Role of necrosis in regulating the growth saturation of multicellular spheroids. Cancer Res., 48: 2432-2439, 1988.
7. Marusic, M., Bajzer. Z., Vuk-Pavlovic, S., and Freyer, J. P. Tumor growth in vivo and as multicellular spheroids compared by mathematical models. Bull. Math. Biol., 56: 617-631, 1994.
8. Sutherland, R. M., Ausserer, W. A., Murphy, B. J., and Laderoute, K. R. Tumor hypoxia and heterogeneity: challenges and opportunities for the future. Semin. Radiat. Oncol., 6: 59-70, 1996.
9. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
10. Sherr, C. J., and Roberts, J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
11. Morgan, D. O. Principles of CDK regulation. Nature (Lond.), 374: 131-134, 1995.
12. Pines, J. Cyclin-dependent kinase inhibitors: the age of crystals. Biochim. Biophys. Acta, 1332: M39-M42, 1997.
13. Hirai, H., Roussel, M. F., Kato, J-Y., Ashmun, R. A., and Sherr, C. J. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol., 15: 2672-2681, 1995.
14. INK4B/MST2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev., 8: 2939-2952, 1994.
15. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
16. Lois, A. F., Cooper, L. T., Geng, Y., Nobori, T., and Carson, D. Expression of the p16 and p15 cyclin-dependent kinase inhibitors in lymphocyte activation and neuronal differentiation. Cancer Res., 55: 4010-4013, 1995.
17. INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation. Mol. Biol. Cell, 7: 1587-1599, 1996.
18. Alcorta, D. A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., and Barrett, J. C. Involvement of the cyclin-dependent kinase inhibitor p16(INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. USA, 93: 13742-13747, 1996.
19. Reed, A. L., Califano, J., Cairns, P., Westra, W. H., Jones, R. M., Koch, W., Ahrendt, S., Eby, Y., Sewell, D., Nawroz, H., Bartek, J., and Sidransky, D. High frequency of p16CDKN2/MTS-1/INK4a inactivation in head and neck squamous carcinoma. Cancer Res., 56: 3630-3633, 1996.
20. INK4A) gene in paraffin-embedded tumor tissues of human stomach, lung, cervix and liver cancers. Exp. Mol. Med, 30: 109-114, 1998.
21. 1 arrest in human cancer cells. Cancer Res., 55: 5187-5190, 1995.
22. Toyoshima, H., and Hunter, T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 75: 67-74, 1994.
23. LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., and Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes Dev., 11: 847-862, 1997.
24. Zhang, H., Hannon, G. J and Beach, D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev., 8: 1750-1758, 1994.
25. LaRue, K. E., Bradbury, M. E., and Freyer, J. P. Regulation of G1 transit by cyclin kinase inhibitors in multicellular spheroid cultures of rat embryo fibroblast cells transformed to different extents. Cancer Res., 58: 1305-1314, 1998.
26. Kerbel, R. S., Rak, J., Kobayashi, H., Man, M. S., St. Croix, B., and Graham, C. H. Multicellular resistance: a new paradigm to explain aspects of acquired drug-resistance of solid tumors. Cold Spring Harbor Symp. Quant. Biol., 59: 661-672, 1994.
27. Ikebe, M., and Tiecher, B. A. Alterations in gene expression between EMT6 mammary carcinoma monolayers and spheroids identified by differential display. Int. J. Oncol., 9: 629-634, 1996.
28. Phillips, R. M., and Clayton, M. R. K. Plateau-phase cultures: an experimental model for identifying drugs which are bioactive within the microenvironment of solid tumours. Br. J. Cancer, 75: 196-201, 1997.
29. Rockwell, S. C., Kallman, R. F., and Fajardo, L. F. Characteristics of a serially transplanted mouse mammary tumor and its tissue culture adapted derivative. J. Natl. Cancer Inst. (Bethesda), 49: 735-747, 1972.
30. Carey, T. E., Takahashi, T., Resnick, L. A., Oettgen, H. F., and Old. L. J. Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc. Natl. Acad. Sci. USA, 73: 3278-3282, 1976.
31. Freyer, J. P., and Sutherland, R. M. Regulation of growth saturation and development of necrosis in EMT6/Ro multicellular spheroids by the glucose and oxygen supply. Cancer Res., 46: 3504-3512, 1986.
32. Freyer, J. P. Rates of oxygen consumption for proliferating and quiescent cells isolated from multicellular tumor spheroids. Adv. Exp. Med. Biol., 345: 335-342, 1994.
33. Freyer, J. P., and Schor, P. L. Automated selective dissociation of cells from different regions of multicellular spheroids. In Vitro Cell. Dev. Biol., 25: 9-19, 1989.
34. Crissman, H. A., Steinkamp, J. A. A new method for rapid and sensitive selection of bromodeoxyuridine in DNA-replicating cells. Exp. Cell Res., 173: 256-261, 1987.
35. Lal, A., Peters, H., St. Croix, B., Haroon, Z. A., Dewhirst, M. W., Strausberg, R. L., Kaanders, J. H., van der Kogel, A. J., and Riggins, G. J. Transcriptional response to hypoxia in human tumors. J. Natl. Cancer Inst. (Bethesda), 93: 1337-1343, 2001.
36. Freyer, J. P., and Schor, P. L. Regrowth kinetics of cells from different regions of multicellular spheroids of four cell lines J. Cell Physiol., 138: 384-392, 1989.
37. Stubbs, M. C., Strachan, G. D., and Hall, D. J. An early S phase checkpoint is regulated by the E2F1 transcription factor. Biochem. Biophys. Res. Commun., 258: 77-80, 1999.
38. Freyer, J. P., Schor, P. L., Jarrett, K. A., Neeman, M., and Sillerud, L. O. Cellular energetics measured by phosphorous NMR spectroscopy are not correlated with chronic nutrient deficiency in multicellular tumor spheroids. Cancer Res., 51: 3831-3837, 1991.
39. Freyer, J. P. Decreased mitochondrial function in quiescent cells isolated from multicellular tumor spheroids. J Cell. Physiol., 176: 138-149, 1998.
40. Kip1 cyclin-dependent kinase inhibitor bound to the cyclin A cdk2 complex. Nature (Lond.), 382: 325-333, 1996.
41. Freyer, J. P., and Schor, P. L., and Saponara, A. G. Partial purification of a protein growth inhibitor from multicellular spheroids. Biochem. Biophys. Res. Comm., 152: 463-368, 1988.
42. Zolzer, F., Stuben, G., Knuhmann, K., Streffer, C., and Sack, H. Quiescent S-phase cells as indicators of extreme physiological conditions in human tumor xenografts. Int. J. Radiat. Oncol. Biol. Phys., 45: 1019-1024, 1999.
43. Waf1 pathway in response to disruption of cell-matrix interactions. J. Biol. Chem., 272: 29091-29098, 1997.
44. Ohtsubo, T., Wang, X., Takahashi, A., Ohnishi, K., Saito, H., Song, C. W., and Ohnishi, T. p53-dependent induction of WAF1 by a low-pH culture condition in human glioblastoma cells. Cancer Res., 57: 3910-3913, 1997.
45. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
46. 1 checkpoint control. Cell, 82: 675-684, 1995.
47. 1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell. Biol., 14: 6264-6277, 1994.
48. Sdi1/Cip1/Waf1 by nitric-oxide-generating vasodilator in vascular smooth muscle cells. J. Biol. Chem., 272: 10050-10057, 1997.
49. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21 CDK- interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
50. Cayrol, C., and Ducommun, B. Interaction of the cyclin-dependent kinase inhibitor p21 with PCNA: a link between cell cycle and DNA repair. Med. Sci., 13: 1259-1265, 1997.
51. Shim, J., Lee, H., Park, J., Kim, H., and Choi, E. A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature (Lond.), 381: 804-807, 1996.
52. Waf1 regulates anchorage-independent growth of HCT116 colon carcinoma cells via E-cadherin expression. Cancer Res., 60: 156-163, 2000.
53. Polyak, K., Kato, J-Y., Solomon, M. J., Sherr, C. J., Massague, J., Roberts, J. M., and Koff, A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor B and contact inhibition to cell cycle arrest. Genes Dev., 8: 9-22, 1994.
54. Kip1) of cyclin-dependent kinase 4 activation. Cell, 79: 487-496, 1994.
55. Kip1 for restriction point control of the fibroblast cell cycle. Science (Wash. DC), 272: 877-880, 1996.
56. Kip1 in cultured mouse mesangial cells: relationship to hypertrophy. Am. J Physiol. Renal Physiol., 42: F348-F356, 1997.
57. Kip1 correlates inversely with anchorage-independent growth of human cancer cell lines. Jpn. J. Cancer Res., 89: 110-115, 1998.
58. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M. Role of the ubiquitin-proteosome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Wash. DC), 269: 682-285, 1995.
59. Kip1 accumulation during the cell cycle. Science (Wash. DC), 271: 1861-1864, 1996.
60. Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene, 15: 629-637, 1997.
61. Kip1 on resistance of tumor cells to anticancer agents. Nat. Med., 11: 1204-1210, 1996.
62. Kip1 coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev., 11: 492-505, 1997.
63. McConnel, B. B., Gregory, F. J., Stott, F. J., Hara, E., and Peters, G. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol. Cell. Biol., 19: 1981-1989, 1999.
64. Mueller-Klieser, W., Freyer, J. P., and Sutherland, R. M. Influence of glucose and oxygen supply conditions on the oxygenation of multicellular spheroids. Br. J. Cancer, 53: 345-353, 1986.
65. Kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am. J. Pathol., 150: 313-323, 1999.
66. Anderson, J., Reddy, V. B., Green, L., Bitterman, P., Borok, R., Maggi-Galluzzi, C., Montironi, R., Wick, M., Gould, V. E., and Gattuso, P. Role of expression of cell cycle inhibitor p27 and MIB-1 in predicting lymph node metastasis in male breast carcinoma. Breast J., 8: 101-107, 2002.
67. De Paola, F., Vecci, A. M., Granato, A. M., Liverani, M., Monti, F., Innoceta, A. M., Gianni, L., Saragoni, L., Ricci, M., Falcini, F., Amadori, D., and Volpi, A. p27/kip1 expression in normal epithelium, benign and neoplastic breast lesions. J. Pathol., 196: 26-31, 2002.
68. Catzavelos, C., Bhattacharya, N., Ung, Y. C., Wilson, J. A., Roncari, L., Sandhu, C., Shaw, P., Yeger, H., Marava-Potzner, I., Kapuska, L., Franssen, E., Pritchard, K. I., and Slingerland, J. M. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.
69. Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., and Roberts, J. M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
70. 1a.b) invasive breast carcinomas. Cancer Res., 57: 1259-1263, 1997.
71. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, J. M., and Pagano, M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinoma. Nat. Med., 3: 231-234, 1997.
72. Sgambato, A., Ratto, C., Faraglia, B., Merico, M., Ardito, R., Schinzari, G., Romano, G., and Cittadini, A. R. Reduced expression and altered subcellular localization of the cyclin- dependent kinase inhibitor p27(Kip1) in human colon cancer. Mol. Carcinog., 26: 172-179, 1999.
73. Singh, S. P., Lipman, J., Goldman, H., Ellis, F. H., Jr., Aizenman, L., Cangi, M. G., Signoretti, S., Chiaur, D. S., Pagano, M., and Loda, M. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res., 58: 1730-1735, 1998.
74. Migita, T., Oda, Y., and Naito, S., and Tsuneyoshi, M. Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer (Phila.), 94: 973-979, 2002.
75. Khoo, M. L., Beasley, N. J., Freeman, J. L., and Asa, S. L. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinomas. J. Clin. Endocrinol. Metab., 87: 1814-1818, 2002.
76. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res., 58: 524-548, 1998.
77. Yang, R. M., Naitoh, H. J., Murphy, M., Wang, H-J., Phillipson, J., DeKernion, J. B., Loda, M., and Reiter, R. E. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol., 159: 941-945, 1998.
78. Cheville, J. C., Lloyd, R. V., Sebo, T. J., Cheng, L., Erickson, L., Bostwick, D. G., Lohse, C. M., and Wollan, P. Expression of p27Kip1 in prostatic adenocarcinoma. Mod. Pathol., 11: 324-328, 1998.
79. Del Pizzo, J. J., Borkowski, A., Jacobs, S. C., and Kyprianou, N. Loss of cell cycle regulators p27 (Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am. J. Pathol., 155: 1129-1136, 1999.
80. Sgambato, A., Migaldi, M., Faraglia, B., Garagnani, L., Romano, G., De Gaetani, C., Ferrari, P., Capelli, G., Trentini, G., and Cittadini, A. Loss of p27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res., 59: 3245-3250, 1999.
81. Jordan, R. C., Bradley, G., and Slingerland, J. Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity. Am. J. Pathol., 152: 585-590, 1998.
82. Florenes, V. A., Maelandsmo, G. M., Kerbel, R. S., Slingerland, J. M., Nesland, J. M., and Holm, R. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am. J. Pathol., 153: 305-312, 1998.
83. Mouriaux, F., Casagrande, F., Pillaire, M. J., Manenti, S., Malecaze, F., Darbon, J. M. Differential expression of G1 cyclins and cyclin-dependent kinase inhibitors in normal and transformed melanocytes. Investig. Opthalmol. Vis. Sci., 39: 876-884, 1998.
84. Burns, K. L., Ueki, K., Jhung, S. L., Koh, J., and Louis, D. N. Molecular-genetic correlates of p16, CDK4, and pRb immunohistochemistry in glioblastomas. J. Neuropathol. Exp. Neurol., 57: 122-130, 1998.
85. INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res., 56: 5023-5032, 1996.
86. Lapointe, J., Lachance, Y., Labrie, Y., and Labrie, C. A p18 mutant defective in CDK6 binding in human breast cancer cells. Cancer Res., 56: 4586-4589, 1996.
87. CDKN2/MTS-1/INK4a in head and neck squamous carcinomas. Cancer Res., 56: 3630-3633, 1996.
88. Reymond, A., and Brent, R. p16 proteins from melanoma-prone families are deficient in binding to CDK4. Oncogene, 11: 1173-1178, 1995.
89. Morosetti, R., Kawamata, N., Gombart, A. F., Miller, C. W., Hatta, Y., Hirama, T., Said, J. W., Tomonaga, M., and Koeffier, H. P. Alterations of the p27Kip1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood, 86: 1924-1930, 1995.
90. Spirin, K. S., Simpson, J. F., Takeuchi, S., Kawamata, N., Miller, C. W., and Koeffier, H. P. p27Kip1 mutation found in breast cancer. Cancer Res., 56: 2400-2404. 1996.
91. Tanaka, C., Yoshimoto, K., Yang, P., Kimura, T., Yamada, S., Moritani, M., Saro, T., and Itakura, M. Infrequent mutations of p27Kip1 gene and trisomy 12 in a subset of human pituitary adenomas. J. Clin. Endocrinol. Metab., 82: 3141-3147, 1997.
92. Morgan, M. B., and Cowper, S. E. Expression of p27 (kip1) in nevi and melanomas. Am. J. Dermatopathol., 21: 121-124, 1999.
93. Qian, X., Jin, L., Kulig, E., and Lloyd, R. V. DNA methylation regulates p27Kip1 expression in rodent pituitary cell lines. Am. J. Pathol., 153: 1475-1482, 1998.
94. Lloyd, R. V., Jin, L., Qian, X., and Kulig, E. Aberrant p27Kip1 expression in endocrine and other tumors. Am. J. Pathol., 150: 401-407, 1997.
95. Canavese, G., Azzoni, C., Pizzi, S., Corleto, V. D., Pasquali, C., Dvoli, C., Crafa, P., Delle Fave, G., and Bordi, C. p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior. Hum. Pathol., 32: 1094-1100, 2001.